Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade.
To assess whether acute nitric oxide (NO) blockade could unmask the vascular actions of endogenous endothelin, we tested the effects of the endothelin type A/type B (ET(A)/ET(B)) receptor antagonist bosentan and the selective ET(A) antagonist FR 139317 on blood pressure, plasma volume, and albumin escape after inhibition of NO synthesis with N(G)-nitro-L-arginine methyl ester (L-NAME). Conscious, chronically catheterized rats received L-NAME in the absence and presence of 17.4 micromol/kg (10 mg/kg) bosentan or 3.8 micromol/kg (2.5 mg/kg I.V., 10 minutes before L-NAME) FR 139317. Red blood cell volume and plasma volume were determined with chromium-51-tagged erythrocytes and iodine-125-labeled albumin, respectively. L-NAME (0.46 to 7.42 micromol/kg [0.125 to 2 mg/kg]) induced a dose-dependent increase in blood pressure, which was attenuated by 60% and 48% with bosentan and FR 139317, respectively (P<.01). L-NAME (7.42 micromol/kg) also increased hematocrit. This effect was associated with an increase in total-body albumin escape, which is reflected by a 14% reduction in plasma volume. Red blood cell volume remained unchanged. L-NAME promoted albumin escape primarily in the lung, heart, liver, kidney, and gastrointestinal tract. Both bosentan and FR 139317 markedly reduced these effects of L-NAME. Furthermore, L-NAME increased plasma levels of immunoreactive endothelin-1 from 8.6+/-0.4 (n=10) to 14.7+/-1.4 pg/mL (n=9, P<.01). These results demonstrate that the pressor response, losses in plasma volume, and increase in albumin escape observed after inhibition of NO synthesis are in part the consequence of unmasking the actions of endogenous endothelin, which are mediated predominantly via ET(A) receptors. These findings suggest a role for endogenous endothelin in the regulation of vascular functions in conditions when NO formation by endothelial cells is impaired.
Filep
J G
JG
Research Center, Maisonneuve-Rosemont Hospital, Department of Medicine, University of Montréal, Québec, Canada.
D000704:Analysis of Variance; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D000077300:Bosentan; D003627:Data Interpretation, Statistical; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood / Q000502:physiology*; D006830:Hydralazine / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D010953:Plasma Volume / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D012709:Serum Albumin / Q000187:drug effects / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000494:pharmacology
D000959:Antihypertensive Agents; D001381:Azepines; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007211:Indoles; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D012709:Serum Albumin; D013449:Sulfonamides; D014665:Vasodilator Agents; C079574:FR 139317; D006830:Hydralazine; D009569:Nitric Oxide; D000077300:Bosentan; D019331:NG-Nitroarginine Methyl Ester